Trial Profile
Phase 2 study of Carboplatin / Nab-paclitaxel + Bevacizumab to non-small-cell lung cancer (non-squamous cell carcinoma) with malignant pleural efussion
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 09 Feb 2021
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Carboplatin (Primary) ; Paclitaxel (Primary)
- Indications Adenocarcinoma; Malignant pleural effusion; Non-small cell lung cancer
- Focus Therapeutic Use
- 05 Feb 2021 Results published in the Investigational New Drugs
- 25 Jan 2021 Status changed from recruiting to discontinued.
- 16 Jun 2016 Planned End Date changed from 31 Jul 2017 to 31 Mar 2019.